Literature DB >> 21904497

The optimization of immunosuppressive and biologic cotherapies in inflammatory bowel disease.

Gert Van Assche1.   

Abstract

Entities:  

Year:  2008        PMID： 21904497      PMCID： PMC3088298     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  4 in total

1.  Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease.

Authors:  Elana A Maser; Renata Villela; Mark S Silverberg; Gordon R Greenberg
Journal:  Clin Gastroenterol Hepatol       Date:  2006-08-22       Impact factor: 11.382

2.  Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease.

Authors:  Severine Vermeire; Maja Noman; Gert Van Assche; Filip Baert; Geert D'Haens; Paul Rutgeerts
Journal:  Gut       Date:  2007-01-17       Impact factor: 23.059

Review 3.  Review article: Altering the natural history of Crohn's disease--evidence for and against current therapies.

Authors:  S Vermeire; G van Assche; P Rutgeerts
Journal:  Aliment Pharmacol Ther       Date:  2007-01-01       Impact factor: 8.171

4.  Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?

Authors:  Stephen B Hanauer
Journal:  Gut       Date:  2007-09       Impact factor: 23.059
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.